4-(2-Phenylthieno[3,2-d]pyrimidin-4-yl)morpholine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并嘧啶酮衍生物
• 英文名称: 4-(2-Phenylthieno[3,2-d]pyrimidin-4-yl)morpholine
• 化学式: C₁₆H₁₅N₃OS
• 分子量: 297.4
• InChiKey: RBDRSWPTRGNKIG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  66.5
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• TOPICAL PHOSPHOINOSITIDE 3-KINASE INHIBITORS
  申请人：VENTHERA, INC.

  公开号：US20200247816A1

  公开（公告）日：2020-08-06

  The present invention provides compounds and topical formulations including the compounds for the treatment of vascular malformations, wherein the compounds are according to formula (I): wherein subscript m, L 1 , R 1 , and L 1 -R 1 are as described herein.

  本发明提供了用于治疗血管畸形的化合物和含有该化合物的局部制剂，其中该化合物符合以下公式（I）：其中下标m，L1，R1和L1-R1如本文所述。
• FORMULATIONS OF PHOSPHOINOSITIDE 3-KINASE INHIBITORS
  申请人：VENTHERA, INC.

  公开号：US20220040193A1

  公开（公告）日：2022-02-10

  The present disclosure provides formulations suitable for topical administration that include compounds of formula (I): one or more excipients, and one or more optional additional components such as an acid or an antioxidant, wherein subscript m, L 1 , and R 1 are as described herein. The formulations provided herein may be sufficiently stable that hydrolysis of the compound of formula (I) in the formulations is less than about 10% under a range of storage conditions. Processes for preparing the formulations and methods of treating vascular malformations with the formulations are also provided herein.
• [EN] TOPICAL PHOSPHOINOSITIDE 3-KINASE INHIBITORS<br/>[FR] INHIBITEURS DE PHOSPHOINOSITIDE 3-KINASE TOPIQUES
  申请人：VENTHERA INC

  公开号：WO2020163525A1

  公开（公告）日：2020-08-13

  The present invention provides compounds and topical formulations including the compounds for the treatment of vascular malformations, wherein the compounds are according to formula (I): wherein subscript m, L1, R1, and L1-R1 are as described herein.